from Reuters: U.S. https://reut.rs/2VwZsGQ
//
The obscure advisory committees at the heart of the U.S. drug pricing debate
April 30, 2019 / / in news, Reuters: U.S. / with No comments /
Expectations were high last year for three new migraine drugs hitting the market from Amgen Inc, Eli Lilly and Co and Teva Pharmaceutical Industries.
from Reuters: U.S. https://reut.rs/2VwZsGQ
//
from Reuters: U.S. https://reut.rs/2VwZsGQ
//
0 comments:
Post a Comment